Objective To explore the risk factors related to postoperative recurrence of uterine fibroid following myomectomy.Methods Four hundred and seventy-three uterine fibroid patients underwent myomectomy were recruited in the case-control study.Leiomyoma characteristics,surgical approach,pathological type and follow-up information were collected by questionnaire.Data were analyzed by correlation analysis and multivariate conditional logistic regression analysis.The calculation of the risk factors associated with the degree of the recurrence after myomectomy was OR and its 95％ confidence interval (95％ CI).Results Among patients,194 cases with recurrence were detected after the 2-7 years follow-up.The number of fibroid removed was the risk factor of postoperative recurrence (OR =2.31,95％ CI:1.57-3.40,P =0.000).Compared with the single fibroid,the risk of recurrence increased 2.31 times in those patients who removed more than two fibroids.Preoperative parity was the protective factor for recurrence (OR =0.63,95％ CI:0.48-0.84,P =0.002).Neither age nor surgical approach or pathological type was associated with the risk of postoperative recurrence related to uterine fibroid following myomectomy.Conlcusion Fibroid number was the risk factor of postoperative recurrence while the preoperative parity was the protective factor.Laparoscopic myomectomy,cellular leiomyoma and muscle intramural leiomyoma did not increase the risk of recurrence.

Objective To translated the Male Osteoporosis Assessment Questionnaire (OPAQTM) into Chinese and test the validity and reliability of it.Methods Translation and cross-cultural adaptation of the original OPAQTM was performed according to the published guidelines.A total of 122 male osteoporosis patients in Xi'an city were included in item analysis,exploratory factor analysis and criterion-related validity and reliability analysis of this Chinese version of OPAQTM.Results A 7-factor structure with 37 items was identified through item analysis and exploratory factor analysis,which explained 73.943％ of the total variance.The ratio of convergent validity of each dimension was exceeded 0.90 and exceeded 0.95 for discriminant validity.The Cronbach's α coefficient for the total OPAQTM score was 0.956.The split-half for the overall scale was 0.858.The test-retest reliability was 0.760 for the overall scale.In relation to criterion validity,the Spearman correlation coefficients ranged from 0.485 to 0.867 between the Chinese version of OPAQTM and the corresponding dimensions of 12-Item Short-Form Health Survey Questionnaire (SF-12),which were significantly correlated,P ＜ 0.01.Conclusions The Chinese version of OPAQTM appears to possess adequate validity and internal consistency.The newly translated Chinese version of OPAQTM may be used to assess the quality of life of male osteoporosis patients in China.

Cytokines are secreted by various cell types and act as critical mediators in many physiological processes, including immune response and tumor progression. Cytokines production is precisely and timely regulated by multiple mechanisms at different levels, ranging from transcriptional to post-transcriptional and posttranslational processes. Monocyte chemoattractant protein-1 induced protein 1 (MCPIP1), a potent immunosuppressive protein, was first described as a transcription factor in monocytes treated with monocyte chemoattractant protein-1 (MCP-1) and subsequently found to possess intrinsic RNase and deubiquitinase activities. MCPIP1 tightly regulates cytokines expression via various functions. Furthermore, cytokines such as interleukin 1 beta (IL-1B) and MCP-1 and inflammatory cytokines inducer lipopolysaccharide (LPS) strongly induce MCPIP1 expression. Mutually regulated MCPIP1 and cytokines form a complicated network in the tumor environment. In this review, we summarize how MCPIP1 and cytokines reciprocally interact and elucidate the effect of the network formed by these components in cancer-related immunity with aim of exploring potential clinical benefits of their mutual regulation.
Chemokine CCL2/immunology* ; Humans ; Interleukin-1beta/immunology* ; Neoplasm Proteins/immunology* ; Neoplasms/pathology* ; Ribonucleases/immunology* ; Transcription Factors/immunology*